ASHP national survey on informatics: Assessment of the adoption and use of pharmacy informatics in U.S. hospitals—2013

Fox, Brent I.; Pedersen, Craig A.; Gumpper, Karl F.

doi:10.2146/ajhp140274

Cited by 31 publications

(39 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…8, 30-32 A recent survey indicated that only 10.7% of hospitals with e-prescribing systems electronically prescribed Schedule II medications in 2013, so most patients must still bring a paper prescription to the pharmacy. 33 Although opioid misuse is a national problem, legitimate access to opioids can also be challenging, particularly for individuals living in predominantly minority areas 30 and for those with chronic pain for whom prescribing of opioid analgesics is frequently necessary. The rescheduling debate for hydrocodone/acetaminophen lasted for years and even prompted congressional action.…”

mentioning

confidence: 99%

Pharmacogenetics for Safe Codeine Use in Sickle Cell Disease

et al. 2016

View full text Add to dashboard Cite

After postoperative deaths in children who were prescribed codeine, several pediatric hospitals have removed it from their formularies. These deaths were attributed to atypical cytochrome P450 2D6 (CYP2D6) pharmacogenetics, which is also implicated in poor analgesic response. Because codeine is often prescribed to patients with sickle cell disease and is now the only Schedule III opioid analgesic in the United States, we implemented a precision medicine approach to safely maintain codeine as an option for pain control. Here we describe the implementation of pharmacogenetics-based codeine prescribing that accounts for CYP2D6 metabolizer status. Clinical decision support was implemented within the electronic health record to guide prescribing of codeine with the goal of preventing its use after tonsillectomy or adenoidectomy and in CYP2D6 ultra-rapid and poor metabolizer (high-risk) genotypes. As of June 2015, CYP2D6 genotype results had been reported for 2468 unique patients. Of the 830 patients with sickle cell disease, 621 (75%) had a CYP2D6 genotype result; 7.1% were ultra-rapid or possible ultra-rapid metabolizers, and 1.4% were poor metabolizers. Interruptive alerts recommended against codeine for patients with high-risk CYP2D6 status. None of the patients with an ultra-rapid or poor metabolizer genotype were prescribed codeine. Using genetics to tailor analgesic prescribing retained an important therapeutic option by limiting codeine use to patients who could safely receive and benefit from it. Our efforts represent an evidence-based, innovative medication safety strategy to prevent adverse drug events, which is a model for the use of pharmacogenetics to optimize drug therapy in specialized pediatric populations. abstractDepartments of a Pharmaceutical Sciences, b Hematology, and c Biostatistics, St. Jude Children's Research Hospital, Memphis, Tennessee; and d Department of Pediatrics, Medical College of Wisconsin, Milwaukee, Wisconsin Dr Gammal collected data, carried out the initial analyses, and drafted the initial manuscript; Drs Crews, Haidar, and Hoffman are coinvestigators on the PG4KDS study; they supervised the collection and analysis of data and critically reviewed and revised the manuscript; Dr Baker created the clinical decision support alerts, collected data, and critically reviewed the manuscript; Drs Barker, Estepp, Wang, and Weiss critically reviewed and revised the manuscript; Ms Pei designed and conducted the statistical analysis; Dr Broeckel supervises all PG4KDS-related genotyping; Dr Relling conceptualized and designed the PG4KDS study, supervised the collection and analysis of data, and critically reviewed and revised the manuscript; Dr Hankins conceptualized and designed the study and critically reviewed and revised the manuscript; and all authors approved the fi nal manuscript as submitted. The use of codeine in pediatric medicine has been questioned following reports of postoperative deaths in children who were prescribed codeine and the subsequent US Food and Drug Admin...

show abstract

mentioning

confidence: 99%

Pharmacogenetics for Safe Codeine Use in Sickle Cell Disease

et al. 2016

View full text Add to dashboard Cite

show abstract

“…[3,12] The results of Pharmacy technology in drug distribution network included Automated transportation system lower that results in report by Alsultam et al and Pedersen, C et al and Fox, B et al while the finding of centralized units dose (Cart filling machines, robotic arms) better than Alsultan report but lower than Pederson c et al and Fox, B et al, result. [4,7,12] The MOH hospital recently started with the automated distribution system, and there some improvement of utilization new pharmacy technology with one-third of hospital pharmacies had planning project for that but still far away from developing countries.…”

Section: Discussionmentioning

confidence: 74%

“…[9][10] Other investigation emphasized on pharmacy automation and technology or pharmacy informatics. [11][12][13][14] However, the most of the local investigation not included the ministry of health hospitals. It is seldom to find in Kingdom of Saudi Arabia or Gulf and Middle East counties studies about pharmacy informatics system in-depth detail manner.…”

Section: Introductionmentioning

confidence: 99%

National Survey of Pharmacy Practice at MOH Hospitals in SAUDI Arabia 2016-2017: Pharmacy Computerized and Technology

Alomi¹,

Alghamdi²,

Alattyh³

2018

JPPCM

View full text Add to dashboard Cite

“…Implementation rates in European hospitals fall far below those in the United States, where for the last decade accreditation has been linked to implementation 1 2. Multidisciplinary collaboration is essential, with pharmacy input and the creation of a smart pump drug library recognised as often being limiting, yet crucial factors, to implementation 3.…”

mentioning

confidence: 99%